<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730349</url>
  </required_header>
  <id_info>
    <org_study_id>CA045-020</org_study_id>
    <secondary_id>2020-000854-85</secondary_id>
    <nct_id>NCT04730349</nct_id>
  </id_info>
  <brief_title>A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer</brief_title>
  <acronym>PIVOT IO 020</acronym>
  <official_title>Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to first, in Part A, assess the safety, tolerability and drug&#xD;
      levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to&#xD;
      estimate the preliminary efficacy in children, adolescents and young adults with recurrent or&#xD;
      treatment-resistant cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities</measure>
    <time_frame>Up to 2 years and 100 days</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 2 years and 100 days</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious AEs (SAEs)</measure>
    <time_frame>Up to 2 years and 100 days</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of drug-related AEs</measure>
    <time_frame>Up to 2 years and 100 days</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 2 years and 100 days</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to 2 years and 100 days</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters: Peak concentration</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters: Trough concentration</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters: Time-averaged concentration</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters: Clearance (CL)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters: Volume of distribution (Vd)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator-assessed objective response rate (ORR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related AEs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities: Hematology tests</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities: Clinical chemistry tests</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Ependymoma</condition>
  <condition>Ewing Sarcoma</condition>
  <condition>High-grade Glioma</condition>
  <condition>Leukemia and Lymphoma</condition>
  <condition>Medulloblastoma</condition>
  <condition>Miscellaneous Brain Tumors</condition>
  <condition>Miscellaneous Solid Tumors</condition>
  <condition>Neuroblastoma</condition>
  <condition>Relapsed, Refractory Malignant Neoplasms</condition>
  <condition>Rhabdomyosarcoma</condition>
  <arm_group>
    <arm_group_label>A1W Dosing schema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A1F Dosing schema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A2W Dosing schema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A2F Dosing schema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B1 Neuroblastoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B2 Ewing sarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B3 Rhabdomyosarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B4 Miscellaneous solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B5 NHL/leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B6 High-grade glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B7 Medulloblastoma and Embryonal Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B8 Ependymoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort B9 Miscellaneous brain tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>A1F Dosing schema</arm_group_label>
    <arm_group_label>A1W Dosing schema</arm_group_label>
    <arm_group_label>A2F Dosing schema</arm_group_label>
    <arm_group_label>A2W Dosing schema</arm_group_label>
    <arm_group_label>Part B: Cohort B1 Neuroblastoma</arm_group_label>
    <arm_group_label>Part B: Cohort B2 Ewing sarcoma</arm_group_label>
    <arm_group_label>Part B: Cohort B3 Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>Part B: Cohort B4 Miscellaneous solid tumors</arm_group_label>
    <arm_group_label>Part B: Cohort B5 NHL/leukemia</arm_group_label>
    <arm_group_label>Part B: Cohort B6 High-grade glioma</arm_group_label>
    <arm_group_label>Part B: Cohort B7 Medulloblastoma and Embryonal Tumors</arm_group_label>
    <arm_group_label>Part B: Cohort B8 Ependymoma</arm_group_label>
    <arm_group_label>Part B: Cohort B9 Miscellaneous brain tumors</arm_group_label>
    <other_name>BMS-936558-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NKTR-214</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>A1F Dosing schema</arm_group_label>
    <arm_group_label>A1W Dosing schema</arm_group_label>
    <arm_group_label>A2F Dosing schema</arm_group_label>
    <arm_group_label>A2W Dosing schema</arm_group_label>
    <arm_group_label>Part B: Cohort B1 Neuroblastoma</arm_group_label>
    <arm_group_label>Part B: Cohort B2 Ewing sarcoma</arm_group_label>
    <arm_group_label>Part B: Cohort B3 Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>Part B: Cohort B4 Miscellaneous solid tumors</arm_group_label>
    <arm_group_label>Part B: Cohort B5 NHL/leukemia</arm_group_label>
    <arm_group_label>Part B: Cohort B6 High-grade glioma</arm_group_label>
    <arm_group_label>Part B: Cohort B7 Medulloblastoma and Embryonal Tumors</arm_group_label>
    <arm_group_label>Part B: Cohort B8 Ependymoma</arm_group_label>
    <arm_group_label>Part B: Cohort B9 Miscellaneous brain tumors</arm_group_label>
    <other_name>Bempegaldesleukin (BEMPEG)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years for Part A and Part B&#xD;
&#xD;
          -  Age up to 30 years for Part B Cohorts B2, B3 and B4&#xD;
&#xD;
          -  Must have received standard of care therapy and there must be no potentially curative&#xD;
             treatment available&#xD;
&#xD;
          -  Histologically confirmed with malignant neoplasms that are refractory, relapsed, or&#xD;
             curative treatments are lacking&#xD;
&#xD;
          -  Must have measurable or evaluable disease based on Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) v1.1 for solid tumors, Response Assessment in Neuro-Oncology&#xD;
             (RANO) or Response Assessment in Pediatric Neuro-Oncology (RAPNO) for central nervous&#xD;
             system tumors, International Pediatric Non-Hodgkin Lymphoma Response Criteria for&#xD;
             non-Hodgkin lymphoma (NHL), revised International Neuroblastoma Response Criteria&#xD;
             (INRC) for neuroblastoma, modified National Comprehensive Cancer Network (NCCN)&#xD;
             Criteria for acute lymphoblastic leukemia, and modified Cheson et al International&#xD;
             Working Group criteria for acute myeloid leukemia&#xD;
&#xD;
          -  Lansky play score for age ≤ 16 years or Karnofsky performance score for age &gt; 16 years&#xD;
             assessed within 2 weeks of enrollment must be ≥ 60&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Osteosarcoma, T-cell/Natural Killer (NK) cell leukemia/lymphoma, and Hodgkin's&#xD;
             lymphoma&#xD;
&#xD;
          -  Need for &gt; 2 antihypertensive medications for management of hypertension (including&#xD;
             diuretics)&#xD;
&#xD;
          -  Known cardiovascular history, including unstable or deteriorating cardiac disease,&#xD;
             within the previous 12 months prior to screening&#xD;
&#xD;
          -  Inadequately treated adrenal insufficiency&#xD;
&#xD;
          -  Active, known, or suspected autoimmune disease&#xD;
&#xD;
          -  Active infection requiring systemic therapy within 14 days prior to first dose&#xD;
&#xD;
          -  Condition requiring systemic treatment with either corticosteroids or other&#xD;
             immunosuppressive medications within 14 days of start of study treatment&#xD;
&#xD;
          -  Prior allogeneic stem cell transplant&#xD;
&#xD;
          -  Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection either&#xD;
             suspected or confirmed within 4 weeks prior to screening&#xD;
&#xD;
        NOTE: other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lyon</city>
        <zip>69373 cedex 03</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille</city>
        <zip>13011</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0042</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0028</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell leukemia/lymphoma/non-Hodgkin lymphoma (NHL)</keyword>
  <keyword>BEMPEG</keyword>
  <keyword>Bempegaldesleukin</keyword>
  <keyword>CD122-Biased Agonist</keyword>
  <keyword>CD122-Biased Cytokine</keyword>
  <keyword>Check point inhibitor</keyword>
  <keyword>Ependymoma</keyword>
  <keyword>Ewing sarcoma</keyword>
  <keyword>High-grade glioma (HGG)/diffuse intrinsic pontine glioma (DIPG)</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>IL-2</keyword>
  <keyword>IL-2 Receptor Agonist</keyword>
  <keyword>Leukemia and lymphoma</keyword>
  <keyword>Medulloblastoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Miscellaneous brain tumors</keyword>
  <keyword>Miscellaneous solid tumors</keyword>
  <keyword>Neuroblastoma</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>NKTR-214</keyword>
  <keyword>NIVO</keyword>
  <keyword>Non-rhabdomyosarcoma soft-tissue sarcomas</keyword>
  <keyword>Opdivo®</keyword>
  <keyword>Pediatric cancer</keyword>
  <keyword>Pediatric malignancy</keyword>
  <keyword>Rhabdomyosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

